Patient Derived XenograftPDX Models Market - Global Forecast To 2030
商品番号 : SMB-42568
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年11月 |
| ページ数 | 367 |
| 図表数 | 521 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
患者由来異種移植片/PDXモデル市場 – タイプ（マウス、ラット）、サービス（モデル作成、特性評価）、移植方法（皮下）、腫瘍タイプ（呼吸器、消化器、婦人科）、用途（前臨床、バイオマーカー） – 2030年までの世界予測
PDXモデル市場は、2025年の3億7,000万米ドルから2030年には6億6,000万米ドルに達し、予測期間中の年平均成長率（CAGR）は12.5%と予想されています。市場を牽引しているのは、主にがん発症率の増加と、ヒト腫瘍の生物学的特性を厳密に再現する効果的な前臨床モデルへの需要の高まりです。腫瘍学研究において、薬剤の有効性評価、バイオマーカーの発見、個別化治療アプローチの情報提供を目的とした患者由来異種移植（PDX）モデルの利用が増えていることも、市場の成長を支えています。さらに、免疫不全マウスモデルの進歩と、PDXプラットフォームと次世代シーケンシング技術の統合により、そのトランスレーショナルバリューが高まっています。しかしながら、PDXモデル開発の高コストと時間集約性、そして倫理的配慮やモデル再現性のばらつきが、市場での広範な採用を依然として抑制しています。
本調査レポートは、PDXモデル市場を、移植方法（皮下移植、同所移植、その他）、種類（マウスモデル、ラットモデル）、腫瘍の種類（消化器系、婦人科系、呼吸器系、泌尿器系、血液系、その他の腫瘍モデル）、用途（前臨床医薬品開発、バイオマーカー分析、トランスレーショナルリサーチ、バイオバンク）、エンドユーザー（製薬・バイオテクノロジー企業、開発業務受託機関（CRO）、学術研究機関）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。
本レポートは、PDXモデル市場の成長に影響を与える主要な要因（推進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーを包括的に分析し、各社の事業概要、製品ポートフォリオ、主要戦略、新製品の発売、買収、そしてPDXモデル市場に関連する最近の動向に関する洞察を提供しています。また、PDXモデル業界エコシステムにおける新興企業の競合分析も含まれています。
本レポートは、市場全体とそのサブセグメントの収益予測を提供することで、市場リーダーと新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、自社の効果的なポジショニングと適切な市場開拓戦略の策定に役立つ洞察を得るのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。
Report Description
The PDX model market is expected to reach USD 0.66 billion in 2030 from USD 0.37 billion in 2025, at a CAGR of 12.5% during the forecast period. The market is primarily driven by the increasing incidence of cancer and the growing demand for effective preclinical models that closely replicate human tumor biology. The increasing use of patient-derived xenograft (PDX) models in oncology research to evaluate drug efficacy, discover biomarkers, and inform personalized treatment approaches further supports market growth. Additionally, advancements in immunodeficient mouse models and the integration of PDX platforms with next-generation sequencing technologies are enhancing their translational value. However, the high cost and time-intensive nature of PDX model development, along with ethical considerations and variability in model reproducibility, continue to restrain widespread market adoption.
“Orthotopic implantation segment is expected to grow at the highest CAGR during the forecast period”
The orthotopic implantation segment is expected to grow at the highest CAGR in the patient-derived xenograft (PDX) model market owing to its superior ability to mimic the natural tumor environment and disease progression seen in human cancers. This technique allows tumor cells to be implanted at their original tissue site, enabling a more accurate representation of tumor-stroma interactions, angiogenesis, and metastatic spread. As a result, orthotopic models provide higher translational relevance and predictive accuracy for assessing drug efficacy and resistance mechanisms compared to other model types. The increasing adoption of targeted therapies and immunotherapies has further fueled the demand for orthotopic models, as they provide a more physiologically relevant context for evaluating therapeutic responses. Additionally, advancements in imaging modalities and microsurgical techniques have improved the reproducibility and monitoring of orthotopic PDX studies, making them more accessible and reliable for preclinical research. These advantages collectively drive the rapid growth of the orthotopic implantation segment in the global PDX model market.
“Gastrointestinal tumor model segment holds the largest share of the market”
The gastrointestinal (GI) tumor model segment holds the largest share of the patient-derived xenograft (PDX) model market, driven by the high global incidence of gastrointestinal malignancies, including colorectal, gastric, pancreatic, and liver cancers. These cancers are among the leading causes of cancer-related mortality, creating a strong demand for reliable preclinical models that accurately replicate tumor heterogeneity and progression. Gastrointestinal PDX models closely preserve the histological and genetic characteristics of patient tumors, enabling more predictive evaluation of therapeutic efficacy and resistance mechanisms. Their robust application in assessing targeted therapies, immunotherapies, and combination treatment strategies has made them a cornerstone of translational oncology research. Furthermore, the growing emphasis on precision medicine and the rising volume of clinical trials focused on GI cancers have accelerated the adoption of these models. Continuous advancements in engraftment techniques and molecular profiling further enhance the utility of gastrointestinal PDX models, solidifying their leading position in the global market.
“The US is expected to grow at the highest CAGR during the forecast period”
The US is expected to register the highest growth rate in the patient-derived xenograft (PDX) model market during the forecast period. This growth is primarily driven by the strong presence of leading pharmaceutical and biotechnology companies, well-established research infrastructure, and extensive oncology research initiatives. The rising prevalence of cancer, coupled with increasing adoption of personalized medicine and targeted therapy development, is significantly boosting the demand for PDX models. Furthermore, growing investment in translational and preclinical cancer research, along with strong collaborations between academic institutions and industry players, is accelerating market expansion.
Additionally, the availability of advanced laboratory facilities, the presence of comprehensive biobanking systems, and supportive government funding for cancer drug discovery further strengthen the country’s position in the global market. The US regulatory environment also promotes innovation while ensuring the reliability and ethical compliance of PDX-based studies. These factors collectively contribute to the rapid adoption of PDX models, reinforcing North America’s leadership in the global market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1 – 25%, Tier 2 – 35%, and Tier 3 – 40%
- By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
- By Region: North America – 35%, Europe – 25%, Asia Pacific – 15%, Latin America – 10%, the Middle East – 10%, and Africa – 5%
JSR Corporation (Japan), WuXi AppTec (China), The Jackson Laboratory (US), Charles River Laboratories (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv (US), Pharmatest Services (Finland), Hera Biolabs (US), EPO Berlin-Buch GmbH (Germany), XenTech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (Taiwan), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (China), Creative Animodel (US), BioDuro (US), Aragen Life Sciences (India), LIDE Shanghai Biotech, Ltd (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co., Ltd. (China), and Shanghai ChemPartner (China) are some of the key companies offering PDX models.
Research Coverage
This research report categorizes the PDX model market by implantation method (subcutaneous implantation, orthotopic implantation, others), type (mouse model, rat model), tumor type (gastrointestinal, gynecological, respiratory, urological, hematological, other tumor models), application (preclinical drug development, biomarker analysis, translational research, biobanks), end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).
The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the PDX model market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the PDX model market. This report also includes a competitive analysis of emerging startups in the PDX model industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market’s pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (growing demand for personalized medicine, technological advancements in PDX models, rising investments in cancer research), restraints (discontinuation of animal models for clinical trials by the FDA), opportunities (emergence of CRISPR in biomedical research), and challenges (development of alternative animal testing methods) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the PDX model market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the PDX model market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including JSR Corporation (Japan), WuXi AppTec (China), The Jackson Laboratory (US), Charles River Laboratories (US), Taconic Biosciences, Inc. (US), among others offering products for the PDX model market. Other companies include BioDuro (US), Aragen Life Sciences (India), LIDE Shanghai Biotech, Ltd (China), Certis Oncology Solutions (US), InnoSer (Netherlands), among others, in the PDX model market
Table of Contents
1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.2.1 MARKET SEGMENTATION & REGIONAL SCOPE 36
1.2.2 YEARS CONSIDERED 37
1.3 STUDY SCOPE 37
1.3.1 INCLUSIONS & EXCLUSIONS 37
1.3.2 CURRENCY CONSIDERED 38
1.4 STAKEHOLDERS 38
1.5 SUMMARY OF CHANGES 39
2 EXECUTIVE SUMMARY 40
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 40
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC IMPERATIVES 43
2.3 DISRUPTIVE TRENDS SHAPING PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 44
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 44
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 45
3 PREMIUM INSIGHTS 46
3.1 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE AND COUNTRY (2024) 46
3.2 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
3.3 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SHARE, BY IMPLANTATION, 2025 VS. 2030 (%) 47
3.4 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SHARE, BY SERVICE, 2024 (%) 48
4 MARKET OVERVIEW 49
4.1 INTRODUCTION 49
4.2 MARKET DYNAMICS 49
4.2.1 DRIVERS 50
4.2.1.1 Growing demand for immuno-oncology and complex biologics 50
4.2.1.2 Rising preference for humanized PDX models 50
4.2.1.3 Focus on government-funded initiatives for cancer research 50
4.2.2 RESTRAINTS 51
4.2.2.1 Introduction of 3D printed models 51
4.2.2.2 Ethical concerns and regulatory restrictions 52
4.2.3 OPPORTUNITIES 53
4.2.3.1 Increasing preference for personalized medicines in oncology 53
4.2.3.2 Growing demand for CDX models for PDX model vendors 53
4.2.4 CHALLENGES 54
4.2.4.1 Limitations of humanized mouse models 54
4.3 UNMET NEEDS & WHITE SPACES 55
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 55
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 55
5 INDUSTRY TRENDS 56
5.1 PORTER’S FIVE FORCES ANALYSIS 56
5.1.1 THREAT OF NEW ENTRANTS 57
5.1.2 THREAT OF SUBSTITUTES 57
5.1.3 BARGAINING POWER OF BUYERS 57
5.1.4 BARGAINING POWER OF SUPPLIERS 57
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 58
5.2 ECOSYSTEM ANALYSIS 58
5.3 VALUE CHAIN ANALYSIS 58
5.4 PRICING ANALYSIS 60
5.4.1 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY KEY PLAYER, 2022−2024 60
5.4.2 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY IMPLANTATION METHOD, 2022−2024 61
5.4.3 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY TUMOR TYPE, 2022−2024 62
5.4.4 AVERAGE SELLING PRICE OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY REGION, 2024 62
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 63
5.6 PATENT ANALYSIS 64
5.6.1 METHODOLOGY 64
5.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 64
5.6.3 LIST OF KEY PATENTS 66
5.7 TRADE DATA ANALYSIS 66
5.7.1 IMPORT DATA FOR HS CODE 106.19.90, 2020–2024 67
5.7.2 EXPORT DATA FOR HS CODE 106.19.90, 2020–2024 68
5.8 IMPACT OF 2025 US TARIFF ON PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 68
5.8.1 KEY TARIFF RATES 69
5.8.2 PRICE IMPACT ANALYSIS 70
5.8.3 KEY IMPACT ON VARIOUS REGIONS 70
5.8.3.1 North America 70
5.8.3.2 Europe 71
5.8.3.3 Asia Pacific 71
5.8.3.4 Rest of the World 71
5.8.4 IMPACT ON END-USE INDUSTRIES 71
5.8.4.1 Pharmaceutical & biotechnology companies 72
5.8.4.2 CROs & CDMOs 72
5.8.4.3 Academic & research institutes 72
5.9 MACROECONOMIC OUTLOOK 73
5.9.1 INTRODUCTION 73
5.9.2 GDP TRENDS AND FORECAST 73
5.9.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY 73
5.9.4 R&D TRENDS IN GLOBAL PHARMA INDUSTRY 74
5.10 KEY CONFERENCES & EVENTS, 2025–2026 74
5.11 INVESTMENT & FUNDING SCENARIO 75
5.11.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 76
5.12 CASE STUDY ANALYSIS 76
5.12.1 IMAGING-READY ORTHOTOPIC PDX FOR PEDIATRIC BRAIN TUMORS 76
5.12.2 HOST-STRAIN SELECTION USING BREAST CANCER PDX 77
5.12.3 RESISTANCE-ANCHORED PDX PANEL TO DESIGN MOUSE CLINICAL TRIAL 77
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 78
6.1 KEY EMERGING TECHNOLOGIES 78
6.1.1 NEXT-GENERATION SEQUENCING 78
6.1.2 GENE EDITING 78
6.2 COMPLEMENTARY TECHNOLOGIES 78
6.2.1 MULTI-OMICS 78
6.2.2 MULTI-MODEL PRECLINICAL IMAGING 79
6.3 TECHNOLOGY ROADMAP 79
6.4 FUTURE APPLICATIONS 79
6.5 IMPACT OF AI/GEN AI ON PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 80
6.5.1 TOP USE CASES & MARKET POTENTIAL 80
6.5.2 CASE STUDIES OF AI IMPLEMENTATION 81
6.5.3 BEST PRACTICES IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS CREATION 81
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 82
6.5.5 HIGH READINESS VS. ADOPTION BARRIERS 83
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 84
7.1 REGIONAL REGULATIONS & COMPLIANCE 84
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
7.1.2 INDUSTRY STANDARDS 86
7.1.2.1 North America 86
7.1.2.2 Europe 88
7.1.2.3 Asia Pacific 89
7.1.2.4 Latin America 91
7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 91
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 92
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 94
8.1 DECISION-MAKING PROCESS 94
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 95
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 96
8.4 UNMET NEEDS FROM END-USE INDUSTRIES 96
9 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE 98
9.1 INTRODUCTION 99
9.2 PDX MODELS 99
9.2.1 MOUSE MODEL 102
9.2.1.1 Proven efficacy of mouse model in cancer research and drug development to boost segment growth 102
9.2.2 RAT MODEL 105
9.2.2.1 Emergence of advanced technologies in PDX rat models to aid market growth 105
9.3 SERVICES 108
9.3.1 MODEL CREATION & EXPANISON SERVICES 111
9.3.1.1 Need for faster passaging of models to to build study-ready cohorts (P1–P3) to boost segment growth 111
9.3.2 MODEL CHARACTERIZATION SERVICES 114
9.3.2.1 Growing demand for biomarker analysis to drive segment growth 114
9.3.3 CRYOPRESERVATION SERVICES 117
9.3.3.1 Reliable and low-passage biobanking services to offer growth opportunities 117
9.3.4 OTHER PDX SERVICES 120
10 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET,
BY IMPLANTATION METHOD 123
10.1 INTRODUCTION 124
10.2 SUBCUTANEOUS IMPLANTATION 124
10.2.1 STANDARDIZED AND SCALABLE PDX MODEL EXPANSION TO DRIVE SEGMENT GROWTH 124
10.3 ORTHOTOPIC IMPLANTATION 127
10.3.1 DEMAND FOR CLINICALLY RELEVANT AND SITE-SPECIFIC PDX MODELS TO BOOST SEGMENT GROWTH 127
10.4 OTHER IMPLANTATION METHODS 131
11 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE 136
11.1 INTRODUCTION 137
11.2 GASTROINTESTINAL TUMOR MODEL 137
11.2.1 HIGH TISSUE AVAILABILITY AND STANDARDIZED ENGRAFTMENT PROTOCOLS TO FUEL MARKET GROWTH 137
11.3 GYNECOLOGICAL TUMOR MODEL 141
11.3.1 EXPANDING ORTHOTOPIC AND HUMANIZED PDX APPLICATIONS
TO DRIVE MARKET 141
11.4 RESPIRATORY TUMOR MODEL 144
11.4.1 INCREASING ADOPTION OF ORTHOTOPIC AND HUMANIZED MODELS
TO BOOST SEGMENT GROWTH 144
11.5 UROLOGICAL TUMOR MODEL 147
11.5.1 EXPANSION OF HORMONE-CONTEXT AND IMMUNE-COMPETENT MODELS
TO FAVOR MARKET ADOPTION 147
11.6 HEMATOLOGICAL TUMOR MODEL 150
11.6.1 RISING ADOPTION OF HUMANIZED AND RELAPSE-DERIVED MODELS
TO DRIVE SEGMENT GROWTH 150
11.7 OTHER TUMOR MODELS 153
12 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION 157
12.1 INTRODUCTION 158
12.2 PRECLINICAL RESEARCH 158
12.2.1 HIGH IMPORTANCE FOR PDX IN EFFICACY CONFIRMATION TO DRIVE MARKET 158
12.3 BIOMARKER ANALYSIS 161
12.3.1 DEMAND FOR MULTI-OMICS TO AUGMENT MARKET GROWTH 161
12.4 TRANSLATIONAL RESEARCH 164
12.4.1 DEMAND FOR PDX MODELS IN CO-CLINICAL TRIAL DESIGNS
TO BOOST SEGMENT GROWTH 164
12.5 BIOBANKING 167
12.5.1 DEMAND FOR PDX MODELS IN SPECIALIZED BANKS
TO SPUR MARKET GROWTH 167
13 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER 171
13.1 INTRODUCTION 172
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 172
13.2.1 INTEGRATION OF TRANSLATIONALLY RELEVANT PDX WORKFLOWS
TO DRIVE MARKET GROWTH 172
13.3 CROS & CDMOS 176
13.3.1 EXPANDED OUTSOURCING THROUGH INTEGRATED WORKFLOWS
TO FUEL MARKET GROWTH 176
13.4 ACADEMIC & RESEARCH INSTITUTES 179
13.4.1 ENHANCED INSTITUTIONAL BIOBANKS AND MULTI-OMIC PROFILING
TO AUGMENT MARKET GROWTH 179
14 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY REGION 182
14.1 INTRODUCTION 183
14.2 NORTH AMERICA 183
14.2.1 US 187
14.2.1.1 US to dominate North American PDX models market during study period 187
14.2.2 CANADA 190
14.2.2.1 Growth research and academic activities on oncology to fuel market growth 190
14.3 EUROPE 193
14.3.1 GERMANY 197
14.3.1.1 Growth in biotechnology industry and strong pharma presence to spur market growth 197
14.3.2 UK 200
14.3.2.1 Increasing focus on cancer research to propel market 200
14.3.3 FRANCE 203
14.3.3.1 Robust research activities in immune-oncology to drive market growth 203
14.3.4 ITALY 206
14.3.4.1 Growing pharmaceutical & biotechnology industry and increasing focus on radiopharmaceuticals to favor market growth 206
14.3.5 SPAIN 209
14.3.5.1 Increasing translational activities to boost market growth 209
14.3.6 REST OF EUROPE 212
14.4 ASIA PACIFIC 215
14.4.1 CHINA 219
14.4.1.1 Favorable investments in life sciences research to drive market 219
14.4.2 JAPAN 222
14.4.2.1 Increasing focus on personalized diagnostics products to drive market 222
14.4.3 INDIA 225
14.4.3.1 Favorable initiatives for drug discovery & development to boost market growth 225
14.4.4 AUSTRALIA 228
14.4.4.1 High number of research institutes to favor market growth 228
14.4.5 SOUTH KOREA 231
14.4.5.1 Innovation in health and biotech sectors to support market uptake 231
14.4.6 REST OF ASIA PACIFIC 234
14.5 LATIN AMERICA 237
14.5.1 BRAZIL 240
14.5.1.1 Increasing investments in biopharmaceutical research to fuel uptake 240
14.5.2 MEXICO 243
14.5.2.1 Expanding healthcare ecosystem to support market growth 243
14.5.3 REST OF LATIN AMERICA 246
14.6 MIDDLE EAST 249
14.6.1 GCC COUNTRIES 252
14.6.1.1 Kingdom of Saudi Arabia 255
14.6.1.1.1 Advanced healthcare sector and prevalence of chronic diseases to boost market 255
14.6.1.2 UAE 258
14.6.1.2.1 Increasing R&D activities and growing demand for personalized medicines to propel market 258
14.6.1.3 Rest of GCC Countries 261
14.6.2 REST OF MIDDLE EAST 264
14.7 AFRICA 267
14.7.1 INCREASING FOCUS ON PRECISION MEDICINE INITIATIVES TO SUPPORT MARKET GROWTH 267
15 COMPETITIVE LANDSCAPE 271
15.1 INTRODUCTION 271
15.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN 271
15.2.1 STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT-DERIVED
XENOGRAFT (PDX) MODELS MARKET, 2022–2025 271
15.3 REVENUE ANALYSIS, 2022–2024 273
15.4 MARKET SHARE ANALYSIS, 2024 273
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 276
15.5.1 STARS 276
15.5.2 EMERGING LEADERS 276
15.5.3 PERVASIVE PLAYERS 276
15.5.4 PARTICIPANTS 276
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 278
15.5.5.1 Company footprint 278
15.5.5.2 Region footprint 279
15.5.5.3 Model type & service footprint 280
15.5.5.4 Tumor type footprint 281
15.5.5.5 Implantation method footprint 282
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 283
15.6.1 PROGRESSIVE COMPANIES 283
15.6.2 RESPONSIVE COMPANIES 283
15.6.3 DYNAMIC COMPANIES 283
15.6.4 STARTING BLOCKS 283
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SME PLAYERS, 2024 285
15.6.5.1 Detailed list of key startups/SMEs 285
15.6.5.2 Competitive benchmarking of key startups/SMEs 286
15.7 COMPANY VALUATION & FINANCIAL METRICS 286
15.7.1 FINANCIAL METRICS 286
15.7.2 COMPANY VALUATION 287
15.8 BRAND/PRODUCT COMPARISON 288
15.9 COMPETITIVE SCENARIO 289
15.9.1 DEALS 289
15.9.2 EXPANSIONS 290
16 COMPANY PROFILES 291
16.1 KEY PLAYERS 291
16.1.1 CHARLES RIVER LABORATORIES 291
16.1.1.1 Business overview 291
16.1.1.2 Products/Services offered 292
16.1.1.3 Recent developments 294
16.1.1.3.1 Deals 294
16.1.1.3.2 Expansions 295
16.1.1.4 MnM view 295
16.1.1.4.1 Key strengths 295
16.1.1.4.2 Strategic choices 296
16.1.1.4.3 Weaknesses & competitive threats 296
16.1.2 THE JACKSON LABORATORY 297
16.1.2.1 Business overview 297
16.1.2.2 Products/Services offered 298
16.1.2.3 Recent developments 299
16.1.2.3.1 Deals 299
16.1.2.3.2 Expansions 300
16.1.2.4 MnM view 300
16.1.2.4.1 Key strengths 300
16.1.2.4.2 Strategic choices 300
16.1.2.4.3 Weaknesses & competitive threats 301
16.1.3 INOTIV 302
16.1.3.1 Business overview 302
16.1.3.2 Products/Services offered 303
16.1.3.3 Recent developments 305
16.1.3.3.1 Expansions 305
16.1.3.4 MnM view 305
16.1.3.4.1 Key strengths 305
16.1.3.4.2 Strategic choices 305
16.1.3.4.3 Weaknesses & competitive threats 306
16.1.4 JSR CORPORATION 307
16.1.4.1 Business overview 307
16.1.4.2 Product/Services offered 308
16.1.4.3 Recent developments 309
16.1.4.3.1 Deals 309
16.1.4.3.2 Expansions 310
16.1.4.4 MnM view 310
16.1.4.4.1 Key strengths 310
16.1.4.4.2 Strategic choices 310
16.1.4.4.3 Weaknesses & competitive threats 310
16.1.5 GENOWAY 311
16.1.5.1 Business overview 311
16.1.5.2 Product/Solutions offered 312
16.1.5.3 MnM view 312
16.1.5.3.1 Key strengths 312
16.1.5.3.2 Strategic choices 312
16.1.5.3.3 Weaknesses & competitive threats 313
16.1.6 WUXI APPTEC + WUXI BIOLOGICS 314
16.1.6.1 Business overview 314
16.1.6.2 Product/Services offered 315
16.1.6.3 Recent developments 316
16.1.6.3.1 Deals 316
16.1.6.3.2 Expansions 318
16.1.7 BIOCYTOGEN PHARMACEUTICALS CO., LTD. 319
16.1.7.1 Business overview 319
16.1.7.2 Product/Services offered 320
16.1.7.3 Recent developments 321
16.1.7.3.1 Product/Service upgrades 321
16.1.7.3.2 Expansions 321
16.1.8 TACONIC BIOSCIENCES, INC. 323
16.1.8.1 Business overview 323
16.1.8.2 Products/Services offered 323
16.1.8.3 Recent developments 324
16.1.8.3.1 Product/Service launches 324
16.1.8.3.2 Deals 325
16.1.8.3.3 Expansions 325
16.1.9 ONCODESIGN SERVICES (ONCODESIGN PRECISION MEDICINE) 326
16.1.9.1 Business overview 326
16.1.9.2 Products/Services offered 326
16.1.10 CHAMPIONS ONCOLOGY, INC. 328
16.1.10.1 Business overview 328
16.1.10.2 Products/Services offered 329
16.1.10.3 Recent developments 329
16.1.10.3.1 Deals 329
16.1.11 PHARMARON 330
16.1.11.1 Business overview 330
16.1.11.2 Products/Services offered 331
16.1.12 SYNGENE INTERNATIONAL LIMITED 333
16.1.12.1 Business overview 333
16.1.12.2 Products/Services offered 334
16.1.13 LABCORP 335
16.1.13.1 Business overview 335
16.1.13.2 Products/Services offered 336
16.1.14 EUROFINS SCIENTIFIC 337
16.1.14.1 Business overview 337
16.1.14.2 Products/Services offered 338
16.1.15 VITALSTAR BIOTECHNOLOGY CO., LTD. 339
16.1.15.1 Business overview 339
16.1.15.2 Products/Services offered 339
16.2 OTHER PLAYERS 340
16.2.1 CREATIVE ANIMODEL 340
16.2.2 JOINN LABORATORIES (CHINA) CO., LTD. 341
16.2.3 CREATIVE BIOLABS 342
16.2.4 ARAGEN LIFE SCIENCES LTD. 343
16.2.5 PHARMTEST SERVICES 344
16.2.6 LIDE SHANGHAI BIOTECH CO., LTD. 345
16.2.7 CERTIS ONCOLOGY SOLUTIONS 345
16.2.8 INNOSER 346
16.2.9 SHANGHAI CHEMPARTNER 346
16.2.10 IVRS AB 347
17 RESEARCH METHODOLOGY 348
17.1 RESEARCH DATA 348
17.1.1 SECONDARY DATA 349
17.1.2 KEY OBJECTIVES OF SECONDARY RESEARCH 349
17.1.3 PRIMARY DATA 349
17.2 MARKET ESTIMATION METHODOLOGY 350
17.2.1 COMPANY REVENUE ANALYSIS: BOTTOM-UP APPROACH 351
17.2.2 INSIGHTS FROM PRIMARY EXPERTS 353
17.2.3 TOP-DOWN APPROACH 353
17.3 GROWTH FORECAST 355
17.4 DATA TRIANGULATION 356
17.5 STUDY ASSUMPTIONS 357
17.6 RESEARCH LIMITATIONS 357
17.7 MARKET FORECAST 358
17.8 RISK ANALYSIS 358
18 APPENDIX 359
18.1 DISCUSSION GUIDE 359
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 363
18.3 CUSTOMIZATION OPTIONS 365
18.4 RELATED REPORTS 365
18.5 AUTHOR DETAILS 366
LIST OF TABLES
TABLE 1 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: INCLUSIONS & EXCLUSIONS 37
TABLE 2 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: IMPACT OF PORTER’S FIVE FORCES 57
TABLE 3 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODEL TYPES, BY KEY PLAYER, 2022−2024 60
TABLE 4 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY IMPLANTATION METHOD, 2022−2024 61
TABLE 5 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY TUMOR TYPE, 2022−2024 62
TABLE 6 AVERAGE SELLING PRICE OF PATIENT-DERIVED XENOGRAFT (PDX) MODEL TYPES, BY REGION, 2024 62
TABLE 7 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 64
TABLE 8 LIST OF KEY PATENTS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2023–2025 66
TABLE 9 IMPORT DATA FOR HS CODE 106.19.90, 2020–2024 (USD THOUSAND) 67
TABLE 10 EXPORT DATA FOR HS CODE 106.19.90, 2020–2024 (USD THOUSAND) 68
TABLE 11 US-AJUSTED RECIPROCAL TARIFF RATES 69
TABLE 12 KEY PRODUCT-RELATED TARIFF: LIVE ANIMALS, PRODUCT OF ANIMAL ORIGIN, MISCELLANEOUS CHEMICAL PRODUCTS 70
TABLE 13 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 70
TABLE 14 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 74
TABLE 15 INVESTMENT & FUNDING ACTIVITY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY KEY PLAYER, 2022−2025 75
TABLE 16 CASE STUDIES OF AI IMPLEMENTATION IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 81
TABLE 17 HIGH READINESS VS. ADOPTION BARRIERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 83
TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 22 VENDOR CERTIFICATIONS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 92
TABLE 23 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 99
TABLE 24 PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 99
TABLE 25 PDX MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 100
TABLE 26 NORTH AMERICA: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100
TABLE 27 EUROPE: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100
TABLE 28 ASIA PACIFIC: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 29 LATIN AMERICA: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 30 MIDDLE EAST: PDX MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 101
TABLE 31 GCC COUNTRIES: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 32 MOUSE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 33 NORTH AMERICA: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 34 EUROPE: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 35 ASIA PACIFIC: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 36 LATIN AMERICA: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 37 MIDDLE EAST: MOUSE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 104
TABLE 38 GCC COUNTRIES: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 39 RAT MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 106
TABLE 40 NORTH AMERICA: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 41 EUROPE: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 42 ASIA PACIFIC: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 43 LATIN AMERICA: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 44 MIDDLE EAST: RAT MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 107
TABLE 45 GCC COUNTRIES: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 46 PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 108
TABLE 47 PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 109
TABLE 48 NORTH AMERICA: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 49 EUROPE: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 50 ASIA PACIFIC: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 51 LATIN AMERICA: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 52 MIDDLE EAST: PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 53 GCC COUNTRIES: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 54 MODEL CREATION & EXPANSION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 112
TABLE 55 NORTH AMERICA: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 56 EUROPE: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 57 ASIA PACIFIC: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 58 LATIN AMERICA: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 59 MIDDLE EAST: MODEL CREATION & EXPANSION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 113
TABLE 60 GCC COUNTRIES: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 61 MODEL CHARATERIZATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 114
TABLE 62 NORTH AMERICA: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 63 EUROPE: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 64 ASIA PACIFIC: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 65 LATIN AMERICA: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 66 MIDDLE EAST: MODEL CHARATERIZATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 67 GCC COUNTRIES: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 68 CRYOPRESERVATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 117
TABLE 69 NORTH AMERICA: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 70 EUROPE: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 71 ASIA PACIFIC: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 72 LATIN AMERICA: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 73 MIDDLE EAST: CRYOPRESERVATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 119
TABLE 74 GCC COUNTRIES: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 75 OTHER PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 120
TABLE 76 NORTH AMERICA: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 77 EUROPE: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 78 ASIA PACIFIC: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 79 LATIN AMERICA: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 80 MIDDLE EAST: OTHER PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 122
TABLE 81 GCC COUNTRIES: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 82 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 124
TABLE 83 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY REGION, 2023–2030 (USD MILLION) 125
TABLE 84 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 85 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 86 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 87 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 88 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY REGION, 2023–2030 (USD MILLION) 126
TABLE 89 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 90 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY REGION, 2023–2030 (USD MILLION) 128
TABLE 91 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 92 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 93 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 94 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 95 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY REGION, 2023–2030 (USD MILLION) 129
TABLE 96 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 97 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY REGION, 2023–2030 (USD MILLION) 131
TABLE 98 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 99 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 100 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 101 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 102 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY REGION, 2023–2030 (USD MILLION) 134
TABLE 103 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 104 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 137
TABLE 105 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 138
TABLE 106 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 107 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 108 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 109 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 110 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 140
TABLE 111 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 112 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 141
TABLE 113 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 114 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 115 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 116 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 117 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 143
TABLE 118 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 119 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 144
TABLE 120 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 121 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 122 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 123 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 124 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 146
TABLE 125 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 126 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 147
TABLE 127 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 128 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 129 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 130 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 131 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 149
TABLE 132 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 133 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 150
TABLE 134 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 135 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 136 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 137 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 138 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 152
TABLE 139 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 140 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY REGION, 2023–2030 (USD MILLION) 154
TABLE 141 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 142 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 143 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 144 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 145 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 146 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 147 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 158
TABLE 148 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION) 159
TABLE 149 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 150 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 151 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 152 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 153 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION) 160
TABLE 154 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 155 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2023–2030 (USD MILLION) 162
TABLE 156 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 157 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 158 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 159 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 160 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2023–2030 (USD MILLION) 163
TABLE 161 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 162 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY REGION, 2023–2030 (USD MILLION) 165
TABLE 163 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 164 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 165 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 166 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 167 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY REGION, 2023–2030 (USD MILLION) 166
TABLE 168 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 169 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY REGION, 2023–2030 (USD MILLION) 168
TABLE 170 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 171 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 172 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 173 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 174 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY REGION, 2023–2030 (USD MILLION) 169
TABLE 175 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 176 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 172
TABLE 177 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 173
TABLE 178 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 179 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 180 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 181 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 182 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 183 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 184 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 185 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 186 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 187 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 188 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 189 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 178
TABLE 190 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 191 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 179
TABLE 192 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 193 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 194 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 195 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 196 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 181
TABLE 197 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 198 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 183
TABLE 199 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 200 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 185
TABLE 201 NORTH AMERICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 202 NORTH AMERICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 203 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 186
TABLE 204 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 186
TABLE 205 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 187
TABLE 206 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 187
TABLE 207 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 188
TABLE 208 US: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 209 US: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 210 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 189
TABLE 211 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 189
TABLE 212 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 190
TABLE 213 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 190
TABLE 214 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 191
TABLE 215 CANADA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 216 CANADA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 217 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 192
TABLE 218 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 192
TABLE 219 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 193
TABLE 220 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 193
TABLE 221 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 222 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 194
TABLE 223 EUROPE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 224 EUROPE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 195
TABLE 225 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 195
TABLE 226 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 196
TABLE 227 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 196
TABLE 228 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 197
TABLE 229 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 197
TABLE 230 GERMANY: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 198
TABLE 231 GERMANY: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 198
TABLE 232 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 198
TABLE 233 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 199
TABLE 234 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 199
TABLE 235 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 200
TABLE 236 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 200
TABLE 237 UK: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 238 UK: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 239 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 201
TABLE 240 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 202
TABLE 241 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 202
TABLE 242 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 203
TABLE 243 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 203
TABLE 244 FRANCE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 245 FRANCE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 246 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 204
TABLE 247 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 205
TABLE 248 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 205
TABLE 249 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 206
TABLE 250 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 206
TABLE 251 ITALY: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 207
TABLE 252 ITALY: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 207
TABLE 253 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 207
TABLE 254 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 208
TABLE 255 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 208
TABLE 256 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 209
TABLE 257 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 209
TABLE 258 SPAIN: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 210
TABLE 259 SPAIN: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 210
TABLE 260 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 210
TABLE 261 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 211
TABLE 262 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 211
TABLE 263 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 212
TABLE 264 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 212
TABLE 265 REST OF EUROPE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 213
TABLE 266 REST OF EUROPE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 213
TABLE 267 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 213
TABLE 268 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 214
TABLE 269 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 214
TABLE 270 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 215
TABLE 271 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 216
TABLE 272 ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 217
TABLE 273 ASIA PACIFIC: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 217
TABLE 274 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 217
TABLE 275 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY TUMOR TYPE, 2023–2030 (USD MILLION) 218
TABLE 276 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 218
TABLE 277 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 219
TABLE 278 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 219
TABLE 279 CHINA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 220
TABLE 280 CHINA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 220
TABLE 281 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 220
TABLE 282 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 221
TABLE 283 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 221
TABLE 284 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 222
TABLE 285 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 222
TABLE 286 JAPAN: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 223
TABLE 287 JAPAN: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 223
TABLE 288 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 223
TABLE 289 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 224
TABLE 290 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 224
TABLE 291 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 225
TABLE 292 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 225
TABLE 293 INDIA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 226
TABLE 294 INDIA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 226
TABLE 295 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 226
TABLE 296 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 227
TABLE 297 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 227
TABLE 298 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 228
TABLE 299 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 228
TABLE 300 AUSTRALIA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 229
TABLE 301 AUSTRALIA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 229
TABLE 302 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 229
TABLE 303 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 230
TABLE 304 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 230
TABLE 305 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 231
TABLE 306 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 231
TABLE 307 SOUTH KOREA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 308 SOUTH KOREA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 309 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 232
TABLE 310 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 233
TABLE 311 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 233
TABLE 312 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 234
TABLE 313 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 234
TABLE 314 REST OF ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 315 REST OF ASIA PACIFIC: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 316 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 235
TABLE 317 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 236
TABLE 318 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 236
TABLE 319 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 237
TABLE 320 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 237
TABLE 321 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 238
TABLE 322 LATIN AMERICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 238
TABLE 323 LATIN AMERICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 238
TABLE 324 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 239
TABLE 325 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 239
TABLE 326 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 240
TABLE 327 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 240
TABLE 328 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 241
TABLE 329 BRAZIL: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 241
TABLE 330 BRAZIL: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 241
TABLE 331 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 242
TABLE 332 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 242
TABLE 333 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243
TABLE 334 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 243
TABLE 335 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 244
TABLE 336 MEXICO: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 337 MEXICO: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 338 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 245
TABLE 339 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 245
TABLE 340 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 246
TABLE 341 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 246
TABLE 342 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 247
TABLE 343 REST OF LATIN AMERICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 247
TABLE 344 REST OF LATIN AMERICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 247
TABLE 345 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 248
TABLE 346 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 248
TABLE 347 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 248
TABLE 348 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 249
TABLE 349 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 249
TABLE 350 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 250
TABLE 351 MIDDLE EAST: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 250
TABLE 352 MIDDLE EAST: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 250
TABLE 353 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 251
TABLE 354 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 251
TABLE 355 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 252
TABLE 356 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 252
TABLE 357 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 253
TABLE 358 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 253
TABLE 359 GCC COUNTRIES: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 253
TABLE 360 GCC COUNTRIES: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 254
TABLE 361 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 254
TABLE 362 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 254
TABLE 363 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 255
TABLE 364 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 255
TABLE 365 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 256
TABLE 366 KINGDOM OF SAUDI ARABIA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 256
TABLE 367 KINGDOM OF SAUDI ARABIA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 256
TABLE 368 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 257
TABLE 369 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 257
TABLE 370 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 258
TABLE 371 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 258
TABLE 372 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 259
TABLE 373 UAE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 374 UAE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 375 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 260
TABLE 376 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 260
TABLE 377 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 261
TABLE 378 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 261
TABLE 379 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 262
TABLE 380 REST OF GCC COUNTRIES: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 262
TABLE 381 REST OF GCC COUNTRIES: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 262
TABLE 382 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 263
TABLE 383 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 263
TABLE 384 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 264
TABLE 385 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 264
TABLE 386 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 265
TABLE 387 REST OF MIDDLE EAST: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 388 REST OF MIDDLE EAST: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 389 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 266
TABLE 390 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 266
TABLE 391 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267
TABLE 392 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 267
TABLE 393 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 268
TABLE 394 AFRICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 268
TABLE 395 AFRICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 268
TABLE 396 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 269
TABLE 397 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 269
TABLE 398 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 270
TABLE 399 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 270
TABLE 400 STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022−2025 271
TABLE 401 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DEGREE OF COMPETITION 274
TABLE 402 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: REGION FOOTPRINT 279
TABLE 403 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: MODEL TYPE & SERVICE FOOTPRINT 280
TABLE 404 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: TUMOR TYPE FOOTPRINT 281
TABLE 405 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: IMPLANTATION METHOD FOOTPRINT 282
TABLE 406 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 285
TABLE 407 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY MODEL TYPE & SERVICE AND REGION 286
TABLE 408 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DEALS, JANUARY 2022− OCTOBER 2025 289
TABLE 409 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: EXPANSIONS, JANUARY 2022− OCTOBER 2025 290
TABLE 410 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 291
TABLE 411 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED 292
TABLE 412 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–OCTOBER 2025 294
TABLE 413 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–OCTOBER 2025 295
TABLE 414 THE JACKSON LABORATORY: COMPANY OVERVIEW 297
TABLE 415 THE JACKSON LABORATORY: PRODUCTS/SERVICES OFFERED 298
TABLE 416 THE JACKSON LABORATORY: DEALS, JANUARY 2022–OCTOBER 2025 299
TABLE 417 THE JACKSON LABORATORY: EXPANSIONS, JANUARY 2022–OCTOBER 2025 300
TABLE 418 INOTIV: COMPANY OVERVIEW 302
TABLE 419 INOTIV: PRODUCTS/SERVICES OFFERED 303
TABLE 420 INOTIV: EXPANSIONS, JANUARY 2022–OCTOBER 2025 305
TABLE 421 JSR CORPORATION: COMPANY OVERVIEW 307
TABLE 422 JSR CORPORATION: PRODUCTS/SERVICES OFFERED 308
TABLE 423 JSR CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025 309
TABLE 424 JSR CORPORATION: EXPANSIONS, JANUARY 2022–OCTOBER 2025 310
TABLE 425 GENOWAY: COMPANY OVERVIEW 311
TABLE 426 GENOWAY: PRODUCTS/SERVICES OFFERED 312
TABLE 427 WUXI APPTEC + WUXI BIOLOGICS: COMPANY OVERVIEW 314
TABLE 428 WUXI APPTEC + WUXI BIOLOGICS: PRODUCTS/SERVICES OFFERED 315
TABLE 429 WUXI APPTEC + WUXI BIOLOGICS: DEALS, JANUARY 2022–OCTOBER 2025 316
TABLE 430 WUXI APPTEC + WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022–OCTOBER 2025 318
TABLE 431 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW 319
TABLE 432 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: PRODUCTS/SERVICES OFFERED 320
TABLE 433 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: PRODUCT/SERVICE UPGRADES, JANUARY 2022–OCTOBER 2025 321
TABLE 434 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: EXPANSIONS, JANUARY 2022–OCTOBER 2025 321
TABLE 435 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW 323
TABLE 436 TACONIC BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED 323
TABLE 437 TACONIC BIOSCIENCES, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2022–OCTOBER 2025 324
TABLE 438 TACONIC BIOSCIENCES, INC.: DEALS, JANUARY 2022–OCTOBER 2025 325
TABLE 439 TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2022–OCTOBER 2025 325
TABLE 440 ONCODESIGN SERVICES (ONCODESIGN PRECISION MEDICINE): COMPANY OVERVIEW 326
TABLE 441 ONCODESIGN SERVICES (ONCODESIGN PRECISION MEDICINE): PRODUCTS/SERVICES OFFERED 326
TABLE 442 CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW 328
TABLE 443 CHAMPIONS ONCOLOGY, INC.: PRODUCTS/SERVICES OFFERED 329
TABLE 444 CHAMPIONS ONCOLOGY, INC.: DEALS, JANUARY 2022–OCTOBER 2025 329
TABLE 445 PHARMARON: COMPANY OVERVIEW 330
TABLE 446 PHARMARON: PRODUCTS/SERVICES OFFERED 331
TABLE 447 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW 333
TABLE 448 SYNGENE INTERNATIONAL LIMITED: PRODUCTS/SERVICES OFFERED 334
TABLE 449 LABCORP: COMPANY OVERVIEW 335
TABLE 450 LABCORP: PRODUCTS/SERVICES OFFERED 336
TABLE 451 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 337
TABLE 452 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED 338
TABLE 453 VITALSTAR BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 339
TABLE 454 VITALSTAR BIOTECHNOLOGY CO., LTD.: PRODUCTS/SERVICES OFFERED 339
TABLE 455 CREATIVE ANIMODEL: COMPANY OVERVIEW 340
TABLE 456 JOINN LABORATORIES (CHINA) CO., LTD.: COMPANY OVERVIEW 341
TABLE 457 CREATIVE BIOLABS: COMPANY OVERVIEW 342
TABLE 458 ARAGEN LIFE SCIENCES LTD.: BUSINESS OVERVIEW 343
TABLE 459 PHARMATEST: BUSINESS OVERVIEW 344
TABLE 460 LIDE SHANGHAI BIOTECH CO., LTD.: COMPANY OVERVIEW 345
TABLE 461 CERTIS ONCOLOGY SOLUTIONS: COMPANY OVERVIEW 345
TABLE 462 INNOSER: COMPANY OVERVIEW 346
TABLE 463 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW 346
TABLE 464 IVRS AB: COMPANY OVERVIEW 347
TABLE 465 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: IMPACT ANALYSIS 358
TABLE 466 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: RISK ANALYSIS 358
LIST OF FIGURES
FIGURE 1 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SEGMENTATION & REGIONAL SCOPE 36
FIGURE 2 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: YEARS CONSIDERED 37
FIGURE 3 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2025 VS. 2030 (USD MILLION) 40
FIGURE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2025 VS. 2030 (USD MILLION) 41
FIGURE 5 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE,
2025 VS. 2030 (USD MILLION) 41
FIGURE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 42
FIGURE 7 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 43
FIGURE 8 GROWING DEMAND FOR IMMUNO-ONCOLOGY AND COMPLEX BIOLOGICS
TO DRIVE MARKET 45
FIGURE 9 US AND PDX MODELS COMMANDED LARGEST MARKET SHARE IN 2024 46
FIGURE 10 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 47
FIGURE 11 SUBCUTANEOUS IMPLANTATION TO DOMINATE MARKET DURING FORECAST PERIOD 47
FIGURE 12 MODEL CREATION & EXPANSION ACCOUNTED FOR LARGEST
MARKET MARKET SHARE IN 2024 48
FIGURE 13 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
FIGURE 14 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: PORTER’S FIVE FORCES 56
FIGURE 15 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: ECOSYSTEM ANALYSIS 58
FIGURE 16 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: VALUE CHAIN ANALYSIS 59
FIGURE 17 AVERAGE SELLING PRICE TREND OF MODEL TYPES, BY KEY PLAYER,
2022–2024 (USD) 61
FIGURE 18 AVERAGE SELLING PRICE OF PATIENT-DERIVED XENOGRAFT (PDX) MODEL TYPES, BY REGION, 2024 (USD) 63
FIGURE 19 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 64
FIGURE 20 PATENT APPLICATIONS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, JANUARY 2014–DECEMBER 2024 65
FIGURE 21 NUMBER OF DEALS AND FUNDING IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022–2025 (USD MILLION) 76
FIGURE 22 TOP USE CASES IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 80
FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON DECISION-MAKING FOR PATIENT-DERIVED XENOGRAFT (PDX) MODELS 94
FIGURE 24 BUYING EVALUATION CRITERIA FOR PATIENT-DERIVED XENOGRAFT (PDX) MODELS 95
FIGURE 25 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX)
MODELS MARKET SNAPSHOT 184
FIGURE 26 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SNAPSHOT 216
FIGURE 27 REVENUE ANALYSIS FOR KEY PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022–2024 (USD MILLION) 273
FIGURE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SHARE ANALYSIS
OF KEY PLAYERS (2024) 274
FIGURE 29 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS) 2024, 277
FIGURE 30 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY FOOTPRINT 278
FIGURE 31 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 284
FIGURE 32 EV/EBITDA OF KEY VENDORS 286
FIGURE 33 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK
BETA OF KEY VENDORS 287
FIGURE 34 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 288
FIGURE 35 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 292
FIGURE 38 JSR CORPORATION: COMPANY SNAPSHOT 308
FIGURE 39 GENOWAY: COMPANY SNAPSHOT 311
FIGURE 40 WUXI APPTEC + WUXI BIOLOGICS: COMPANY SNAPSHOT 315
FIGURE 41 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT 320
FIGURE 42 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT 328
FIGURE 43 PHARMARON: COMPANY SNAPSHOT 331
FIGURE 44 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT 333
FIGURE 45 LABCORP: COMPANY SNAPSHOT 336
FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 338
FIGURE 47 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: RESEARCH DESIGN 348
FIGURE 48 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 350
FIGURE 49 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 350
FIGURE 50 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024) 351
FIGURE 51 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: ILLUSTRATIVE REVENUE ANALYSIS OF CHARLES RIVER LABORATORIES (2024) 352
FIGURE 52 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET SIZE VALIDATION FROM PRIMARY SOURCES 353
FIGURE 53 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 353
FIGURE 54 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: CAGR PROJECTIONS 355
FIGURE 55 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: DATA TRIANGULATION METHODOLOGY 356
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11